Bristol-Myers Squibb's Daklinza Gets EU Nod
Friday, October 3, 2014
Source: FDA News
Bristol-Myers Squibb says it will soon start marketing its hepatitis C drug Daklinza in the European Union, following its approval last week.
Daklinza (daclatasvir) is indicated for use in conjunction with other therapies, such as Gilead Sciences' blockbuster drug Sovaldi (sofosbuvir).